Marengo Therapeutics and Ipsen announced Monday that they have entered into a strategic, multi-year partnership to usher two of Marengo’s precision T cell immuno-oncology candidates into the clinic.
https://www.pharmalive.com/wp-content/uploads/2022/08/BioSpaceMarengo8-1-2022.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-08-01 11:11:042022-08-01 11:11:04Ipsen invests potential $1.6B to turbo-charge Marengo’s path to the clinic
